Korea Investment Partners backs Eloxx Pharmaceuticals' $30m Series C

Korea Investment Partners backs Eloxx Pharmaceuticals' $30m Series C

Medicine, biotechnology, DNA, genetics and healthcare. Image: Pixabay

Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations, has secured an addition $6 million to close its Series C round at $30 million.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter